Sales & Marketing
Key payer backs Ultragenyx' rare rickets drug at $200,000 pe...
The FDA has approved the first therapy for a rare inherited form of rickets – Ultragenyx’s Crysvita (burosumab), priced at up to $200,000 per year.
